REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its first quarter 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, May 7, 2025. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update o ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on Wall Street's projections, several notable biotechs could see their shares soar in the next 12 months.Of course, it wouldn't be wise to rush to invest in these companies for that reason alone, but it might be worth looking deeper into what the Street considers severely undervalued drugmakers. Read on to learn m ...

Core Insights - Roche Holdings AG presented new data on trontinemab at the AD/PD 2025 International Conference, highlighting its potential in Alzheimer's disease treatment and the Elecsys pTau181 plasma test's ability to rule out amyloid pathology [1][4]. Group 1: Trontinemab Study Results - The ongoing Phase 1b/2a Brainshuttle AD study of trontinemab showed dose-dependent rapid amyloid depletion from the brain [1]. - Preliminary results indicated that trontinemab reduced amyloid levels below the 24 centiloid threshold in 81% of participants (21 out of 26) in the 3.6 mg/kg dose group after 28 weeks [6]. - The study reported a favorable safety profile, with amyloid-related imaging abnormalities (ARIA-E) observed in less than 5% of participants, and only one case associated with mild symptoms [3]. Group 2: Elecsys pTau181 Plasma Test - Results from a multicenter study involving 604 participants demonstrated the Elecsys pTau181 plasma test's potential to accurately rule out amyloid pathology in individuals with cognitive impairment [4]. - Roche anticipates that the Elecsys pTau181 test will be available in Europe by late 2025, followed by the U.S. [4]. Group 3: Future Developments - Roche plans to initiate a Phase 3 program for trontinemab later this year [4]. - The company continues to reinforce its commitment to advancing research in Alzheimer's disease through ongoing studies and new testing methods [4]. Group 4: Market Reaction - Following the presentation of the new data, Roche's stock (RHHBY) closed lower by 4.37% to $37.65 [5].

Core Insights - Soligenix Inc. is a late-stage biopharmaceutical company focused on developing products for rare diseases with unmet medical needs [1][5] - The company has selected IBN to lead its corporate communications efforts, leveraging IBN's extensive distribution network to enhance visibility [1][4] Company Overview - Soligenix operates through two main segments: Specialized BioTherapeutics, which targets oncology and inflammation therapies, and Public Health Solutions, which focuses on vaccines and therapeutics for biothreats and infectious diseases [2] - The company is advancing multiple late-stage clinical programs, including HyBryte™ (SGX301) for cutaneous T-cell lymphoma, and other candidates for psoriasis (SGX302), oral mucositis (SGX942), and Behçet's disease (SGX945) [2][5] Public Health Initiatives - The Public Health Solutions segment includes development programs for vaccines against ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™), supported by approximately $60 million in non-dilutive government grants and contracts [3][6] - The vaccine development utilizes proprietary heat stabilization technology known as ThermoVax® [6] Strategic Partnerships - IBN will utilize its investor-focused distribution network, which includes over 5,000 syndication outlets and a large social media following, to increase awareness for Soligenix [4][5] - IBN has over 19 years of experience and has assisted more than 500 client partners, positioning it to effectively reach a broad audience [5]

Core Viewpoint - Soligenix, Inc. is focused on advancing its clinical programs and achieving significant development milestones, particularly in the treatment of rare diseases with unmet medical needs, while managing its financial resources effectively [2][9]. Recent Accomplishments - The company has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ in early-stage cutaneous T-cell lymphoma (CTCL) and has reported positive interim results from an open-label study of HyBryte™ [7][9]. - Formation of a European Medical Advisory Board to provide strategic guidance for the ongoing clinical studies [7]. Financial Results - For the year ended December 31, 2024, Soligenix reported revenues of $0.1 million, a decrease from $0.8 million in the previous year, primarily due to timing issues with government grant funding [4]. - The net loss for the year was $8.3 million, or ($4.98) per share, compared to a net loss of $6.1 million, or ($12.66) per share, in the prior year, influenced by a reverse stock split and increased research and development expenses [5][6]. - Research and development expenses rose to $5.2 million from $3.3 million, driven by costs related to new clinical trials [6]. Cash Position - As of December 31, 2024, the company had approximately $7.8 million in cash, which is expected to support operations through 2025 while exploring various strategic options for funding [2][8].

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Q4 2024 Results Conference Call March 3, 2025 8:00 AM ET Company Participants Helen Rubinstein - Vice President of Investor Relations & Communications Paul Berns - Chief Executive Officer Josh Pinto - President Bill Aurora - Chief Operating & Development Officer Michael Milligan - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Douglas Tsao - H.C. Wainwright Delma Caiati - Guggenheim Paul Matteis - Stifel Sam Lee - Mizuho Tes ...

ANI Pharmaceuticals (ANIP) Q4 2024 Earnings Call February 28, 2025 08:00 AM ET Company Participants Lisa Wilson - Founder and PresidentNikhil Lalwani - President and CEOChristopher Mutz - Senior Vp & Head of Rare DiseaseStephen Carey - Senior VP of Finance & CFOGary Nachman - Managing Director - Equity ResearchJeevan Larson - Equity Research AssociateGlen Santangelo - Managing Director Conference Call Participants David Amsellem - Sr. Research AnalystVamil Divan - Managing Director & Senior Research Analyst ...

Catalyst Pharmaceuticals (CPRX) Q4 2024 Earnings Call February 27, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Chief Commercial OfficerGary Ingenito - Chief Medical & Regulatory OfficerBenjamin Paluch - Equity Research Senior AssociateRohan Mathur - Equity Research AssociateFelix Ampomah - Senior Associate Conference Call Participants Charles Duncan - AnalystPavan Patel - AnalystAsim Rana - Equity AnalystJoseph Catanzaro - Director & ...

Catalyst Pharmaceuticals (CPRX) Q4 2024 Earnings Call February 27, 2025 08:30 AM ET Company Participants Michael Kalb - Executive VP & CFORichard Daly - President & CEOJeff Del Carmen - Chief Commercial OfficerGary Ingenito - Chief Medical & Regulatory OfficerBenjamin Paluch - Equity Research Senior AssociateRohan Mathur - Equity Research AssociateFelix Ampomah - Senior Associate Conference Call Participants Charles Duncan - AnalystPavan Patel - AnalystAsim Rana - Equity AnalystJoseph Catanzaro - Director & ...